Pancreatic cancer is the 10th deadliest form of cancer in the United States, according to the National Cancer Institute.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three ...

A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...

The mRNA vaccine works by targeting genetic mutations found in pancreatic cancer, alerting the immune system to recognize and ...

A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study ...

The phase 1 trial results, published Feb. 19 in Nature, evaluated the personalized mRNA neoantigen vaccine autogene cevumeran in combination with surgery, immunotherapy drug atezolizumab and ...

Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

A personalized mRNA vaccine may reduce the risks of pancreatic cancer returning after surgery, according to a preliminary ...

There is new hope in the fight against pancreatic cancer after early trials showed that personalized mRNA vaccines can target ...

"GMA" examines a preliminary study where a personalized mRNA vaccine showed promise in reducing the risk of pancreatic cancer ...